Landing
Forget antibiotics: Why the next big medical breakthrough is a beam of light
Lindo Life Science, founded by Robert Gangi, is changing the battle against antimicrobial resistance (AMR) with the Lindo Tube, which uses occupant-safe antimicrobial blue light to shatter 99.9% of bacteria. This breakthrough prevents Ventilator-Associated Pneumonia (VAP), a secondary infection affecting nearly one in four intubated patients, and has been validated by a collaboration with the Mayo Clinic.
Why the Future of Heart Health is ‘Cuffless’
After 25 years in the Emergency Room, Dr. Joe is pioneering a new era in heart health with Zaplutus Health’s Ora Connect, a revolutionary ‘peel-and-stick’ wearable providing hospital-grade, continuous, cuff-less blood pressure data to transform patient care both inside and outside the hospital.
Inside the Australian Life Sciences Boom: Renowned Investors, World-Class Partners, World-Leading Breakthroughs
The Australian life sciences sector is experiencing an unprecedented boom, marked by world-leading partnerships, rapid regulatory progress, and significant capital investment. The Emergence Preview Series showcased companies with technologies already in clinical trials and backed by renowned global institutions and investors. This moment feels different due to the maturity and global reach of Australian life sciences innovation.
The Great Life Science Reset: Why the “Sick Care” Model is Failing
The data reveals a significant transition: the end of the traditional sick care model and the rise of a proactive healthcare ecosystem. Learn how smart money is utilising AI to cut drug discovery times in half, transform diagnostics to detect complex diseases in days, and create efficiencies to scale the healthcare system without a proportional increase in costs.
Anthropic Economic Index: Why the “Skills Gap” is About to Explode
The latest Anthropic Economic Index warns that AI is not a leveller for junior staff but a force multiplier for senior engineers, accelerating the skills gap. The transition requires a focus on workflow design and redesigning roles around where the 12x leverage actually exists.
The Bridge Is Built: Why the NYSE’s Move Changes Capital Allocation Forever
The New York Stock Exchange has fundamentally changed the future of finance by announcing a dedicated platform for the trading and on-chain settlement of tokenised securities. This pivotal move signals the institutionalisation of digital assets, bringing 24/7 operations, instant (T+0) settlement, and new advantages for private wealth allocators.
Why Life Sciences Is Now One of My Highest Conviction Investment Themes
In 17 years, we’ve watched themes rise and fall. Today, life sciences is a portfolio-defining opportunity. This is not speculation; it is pattern recognition based on the staggering returns from companies like Telix and Neuren, and the convergence of AI, clear regulatory pathways, and a shift in capital back toward real science.
The GPS for Oncology: Ending the era of ‘blind’ cancer removal
Ferronova is pioneering the “GPS for Oncology” with magnetic nanoparticles, creating a high-definition roadmap to precisely trace cancer in lymph nodes and eliminate the guesswork of traditional surgery, a move from “search and destroy” to “trace and target.”
The Shift: Why Big Tech Stopped Buying Companies and Started Buying Brains
The unprecedented speed of AI innovation has triggered a structural shift in how Big Tech consolidates power. The era of the full company acquisition is pausing, replaced by a new model: buying brains and renting IP through rapid, high-value licensing deals and surgical talent extraction that sidesteps regulatory hurdles.
Backed By Leading Investment Groups and Family Offices
